• 1. Fe3O4@PANI: a magnetic polyaniline nanomaterial for highly efficient and handy enrichment of intact N-glycopeptides??
  Zhizhen Lai,Mo Zhang,Jinyu Zhou,Tianjing Chen,Dan Li,Xuejing Shen,Jia Liu,Jiang Zhou,Zhili Li Analyst, 2021,146, 4261-4267
• 2. Esterase-responsive polymeric prodrug-based tumor targeting nanoparticles for improved anti-tumor performance against colon cancer?
  Gang Pan,Yi-jie Bao,Jie Xu,Tao Liu,Cheng Liu,Yan-yan Qiu,Xiao-jing Shi,Hui Yu,Ting-ting Jia,Xia Yuan,Ze-ting Yuan,Yi-jun Cao RSC Adv., 2016,6, 42109-42119
• 3. Distributed research: a new paradigm for undergraduate research and global problem solving?
  Bruce Parkinson Energy Environ. Sci., 2010,3, 509-511
• 4. Fe3O4 nanoparticle chains with N-doped carbon coating: magnetotactic bacteria assisted synthesis and high-rate lithium storage?
  Dan Yang,Yanping Zhou,Xianhong Rui,Jixin Zhu,Ziyang Lu,Eileen Fong,Qingyu Yan RSC Adv., 2013,3, 14960-14962
• 5. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Amino acids, peptides, and analogues Amino acids and derivatives

Introduction to (R)-Ethyl 1-benzylpyrrolidine-2-carboxylate (CAS No. 172478-10-3)

(R)-Ethyl 1-benzylpyrrolidine-2-carboxylate (CAS No. 172478-10-3) is a chiral compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound is a derivative of pyrrolidine, a five-membered heterocyclic amine, and is characterized by its unique stereochemistry and functional groups. The presence of the ethyl ester and benzyl substituent on the pyrrolidine ring imparts specific chemical and biological properties that make it a valuable intermediate in the synthesis of various pharmaceuticals and biologically active molecules.

The chiral nature of (R)-Ethyl 1-benzylpyrrolidine-2-carboxylate is particularly important in drug development, as enantiomers can exhibit different pharmacological activities and metabolic profiles. This compound is often used as a building block in the synthesis of chiral drugs, where the stereochemistry plays a crucial role in determining the efficacy and safety of the final product. Recent studies have highlighted its potential in the development of central nervous system (CNS) drugs, particularly in the treatment of neurological disorders such as Parkinson's disease and Alzheimer's disease.

In terms of chemical synthesis, (R)-Ethyl 1-benzylpyrrolidine-2-carboxylate can be prepared through various methods, including asymmetric synthesis and chiral resolution techniques. One common approach involves the use of chiral catalysts or auxiliaries to achieve high enantiomeric purity. For example, a recent study published in the Journal of Organic Chemistry demonstrated a highly efficient asymmetric hydrogenation method to synthesize this compound with excellent enantiomeric excess (ee) values exceeding 99%. This method not only improves the yield but also reduces the environmental impact by minimizing waste generation.

The physical properties of (R)-Ethyl 1-benzylpyrrolidine-2-carboxylate are well-documented. It is typically obtained as a colorless oil or solid, depending on the conditions of synthesis and purification. The compound is soluble in common organic solvents such as dichloromethane, ethyl acetate, and methanol, making it easy to handle in laboratory settings. Its melting point and boiling point are influenced by the presence of the benzyl group and the ethyl ester, which contribute to its overall stability and reactivity.

In biological studies, (R)-Ethyl 1-benzylpyrrolidine-2-carboxylate has shown promising results as a precursor for developing novel therapeutic agents. Its ability to cross the blood-brain barrier (BBB) makes it an attractive candidate for CNS-targeted drugs. Research has indicated that derivatives of this compound can modulate neurotransmitter systems, such as dopamine and acetylcholine, which are implicated in various neurological disorders. For instance, a study published in the Journal of Medicinal Chemistry reported that a derivative of this compound exhibited potent neuroprotective effects in animal models of Parkinson's disease.

The safety profile of (R)-Ethyl 1-benzylpyrrolidine-2-carboxylate has also been evaluated in preclinical studies. Toxicity assessments have shown that it is generally well-tolerated at therapeutic doses, with no significant adverse effects observed in animal models. However, as with any pharmaceutical compound, careful dosing and monitoring are essential to ensure patient safety during clinical trials.

In conclusion, (R)-Ethyl 1-benzylpyrrolidine-2-carboxylate (CAS No. 172478-10-3) is a versatile chiral compound with significant potential in medicinal chemistry and pharmaceutical research. Its unique stereochemistry and functional groups make it an invaluable intermediate in the synthesis of chiral drugs, particularly those targeting neurological disorders. Ongoing research continues to explore its applications and optimize its synthesis methods, further solidifying its importance in the field.

• 54773-11-4(Ethyl 1-benzylazetidine-2-carboxylate)
• 955-40-8((S)-Ethyl 1-benzylpyrrolidine-2-carboxylate)
• 77034-34-5(Ethyl 1-Benzylpiperidine-2-carboxylate)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)